Top

BMC Cancer

Published in:

Open Access 01-12-2024 | Gastric Cancer | Research

Comprehensive analysis of T-cell regulatory factors and tumor immune microenvironment in stomach adenocarcinoma

Authors: Shuchang Wang, Weifeng Zhang, Xinrui Wu, Zhu Zhu, Yuanbiao Chen, Wangrui Liu, Junnfei Xu, Li Chen, Chun Zhuang

Published in: BMC Cancer | Issue 1/2024

Abstract

Background

Gastric cancer (GC) is one of the most prevalent malignant tumors worldwide and is associated with high morbidity and mortality rates. However, the specific biomarkers used to predict the postoperative prognosis of patients with gastric cancer remain unknown. Recent research has shown that the tumor microenvironment (TME) has an increasingly positive effect on anti-tumor activity. This study aims to build signatures to study the effect of certain genes on gastric cancer.

Methods

Expression profiles of 37 T cell-related genes and their TME characteristics were comprehensively analyzed. A risk signature was constructed and validated based on the screened T cell-related genes, and the roles of hub genes in GC were experimentally validated.

Results

A novel T cell-related gene signature was constructed based on CD5, ABCA8, SERPINE2, ESM1, SERPINA5, and NMU. The high-risk group indicated lower overall survival (OS), poorer immune efficacy, and higher drug resistance, with SERPINE2 promoting GC cell proliferation, according to experiments. SERPINE2 and CXCL12 were significantly correlated, indicating poor OS via the Youjiang cohort.

Conclusions

This study identified T cell-related genes in patients with stomach adenocarcinoma (STAD) for prognosis estimation and proposed potential immunotherapeutic targets for STAD.

Available only for authorised users

Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.CrossRefPubMed

Okines A, Verheij M, Allum W, Cunningham D, Cervantes A. ESMO guidelines Working Group gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v50–4.PubMedCrossRef

Suzuki H, Oda I, Abe S, Sekiguchi M, Mori G, Nonaka S, et al. High rate of 5-year survival among patients with early gastric cancer undergoing curative endoscopic submucosal dissection. Gastric Cancer. 2016;19:198–205.PubMedCrossRef

Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, et al. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 2015;385:977–1010.PubMedCrossRef

Banks M, Graham D, Jansen M, Gotoda T, Coda S, di Pietro M, et al. British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma. Gut. 2019;68:1545–75.PubMedCrossRef

Jiang K, Li L, Xie Y, Xie D, Xiao Q. High ADAMTS18 expression is associated with poor prognosis in stomach adenocarcinoma. Oncol Lett. 2020;20(5):211.PubMedPubMedCentralCrossRef

Zhang B, Li Y, Yang L, Chen Y. A four-gene-based risk score with High Prognostic Value in Gastric Cancer. Front Oncol. 2021;11:584213.PubMedPubMedCentralCrossRef

Song Z, Wu Y, Yang J, Yang D, Fang X. Progress in the treatment of Advanced Gastric Cancer. Tumour Biol: J Int Soc Oncodevelopmental Biol Med. 2017;39(7):1010428317714626.CrossRef

Fuchs CS, Doi T, Jang RW et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer. JAMA Oncol. 2018;4(5).

10.

Zeng D, Zhou R, Yu Y, et al. Gene expression profiles for a prognostic immunoscore in gastric cancer. Br J Surg. 2018;105:1338–48.PubMedCrossRef

11.

Zeng D, Li M, Zhou R, et al. Tumor microenvironment characterization in gastric cancer identifies prognostic and immunotherapeutically relevant gene signatures. Cancer Immunol Res. 2019;7:737–50.PubMedCrossRef

12.

Zeng D, Ye Z, Wu J, et al. Macrophage correlates with immunophenotype and predicts anti-PD-L1 response of urothelial cancer. Theranostics. 2020;10:7002–14.PubMedPubMedCentralCrossRef

13.

Fridman WH, Zitvogel L, Sautès-Fridman C, et al. The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. 2017;14:717–34.PubMedCrossRef

14.

Chen Y, Zhang S, Wang Q, Zhang X. Tumor-recruited M2 macrophages promote gastric and breast cancer metastasis via M2 macrophage-secreted CHI3L1 protein. J Hematol Oncol. 2017;10:36.PubMedPubMedCentralCrossRef

15.

Traves PG, Luque A, Hortelano S. Macrophages, inflammation, and tumor suppressors: ARF, a new player in the game. Mediat Inflamm. 2012;2012:568783.CrossRef

16.

1.Song W, Ren J, Xiang R, Kong C, Fu T. Identification of pyroptosis-related subtypes, the development of a prognosis signature, and characterization of tumor microenvironment infiltration in colorectal cancer. Oncoimmunology. 2021;10(1):1987636.PubMedPubMedCentralCrossRef

17.

Galli F, Aguilera JV, Palermo B, Markovic SN, Nisticò P, Signore A. Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy. J Exp Clin Cancer Res. 2020;39:1–21.CrossRef

18.

Shitara K, Özgüroğlu M, Bang YJ, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018;392(10142):123–33.PubMedCrossRef

19.

Abramson JS, et al. Transcend NHL 001: immunotherapy with the CD19-directed CAR T-cell product JCAR017 results in high complete response rates in relapsed or refractory B-cell non-hodgkin lymphoma. Blood. 2016;128:4192–4192.CrossRef

20.

Chen Z, et al. In vivo CD8 + T-cell CRISPR screening reveals control by Fli1 in infection and cancer. Cell. 2021;184:1262–80.PubMedPubMedCentralCrossRef

21.

Li J, Li W, Huang K, Zhang Y, Kupfer G, Zhao Q. Chimeric antigen receptor T-cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward. J Hematol Oncol. 2018;11(1):22.PubMedPubMedCentralCrossRef

22.

Legut M, Gajic Z, Guarino M, Daniloski Z, Rahman JA, Xue X, Lu C, Lu L, Mimitou EP, Hao S, Davoli T, Diefenbach C, Smibert P, Sanjana NE. A genome-scale screen for synthetic drivers of T-cell proliferation. Nature. 2022;603(7902):728–35.PubMedPubMedCentralCrossRef

23.

Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27–30. https://doi.org/10.1093/nar/28.1.27.CrossRefPubMedPubMedCentral

24.

Kanehisa M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 2019;28(11):1947–51. https://doi.org/10.1002/pro.3715. Epub 2019 Sep 9.CrossRefPubMedPubMedCentral

25.

Kanehisa M, Furumichi M, Sato Y, Kawashima M, Ishiguro-Watanabe M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 2023;51(D1):D587–92. https://doi.org/10.1093/nar/gkac963.CrossRefPubMed

26.

Shao W, Yang Z, Fu Y, Zheng L, Liu F, Chai L, Jia J. The pyroptosis-related signature predicts prognosis and indicates Immune Microenvironment Infiltration in Gastric Cancer. Front Cell Dev Biol. 2021;9:676485.PubMedPubMedCentralCrossRef

27.

Wang N, Liu D. Identification and validation a necroptosis–related Prognostic signature and Associated Regulatory Axis in stomach adenocarcinoma. Onco Targets Ther. 2021;14:5373–83.PubMedPubMedCentralCrossRef

28.

Xiao R, Wang S, Guo J, Liu S, Ding A, Wang G, Li W, Zhang Y, Bian X, Zhao S, Qiu W. Ferroptosis-related gene NOX4, CHAC1 and HIF1A are valid biomarkers for stomach adenocarcinoma. J Cell Mol Med. 2022;26(4):1183–93.PubMedPubMedCentralCrossRef

29.

Xu P, Liu S, Song S, Yao X, Li X, Zhang J, Liu Y, Zheng Y, Gao G, Xu J. Identification and validation of a novel angiogenesis-related gene signature for predicting prognosis in gastric adenocarcinoma. Front Oncol. 2023;12:965102.PubMedPubMedCentralCrossRef

30.

Wang X, Zhang W, Guo Y, Zhang Y, Bai X, Xie Y. Identification of critical prognosis signature associated with lymph node metastasis of stomach adenocarcinomas. World J Surg Oncol. 2023;21(1):61.PubMedPubMedCentralCrossRef

31.

Chen F, Wang Y, Zhang X, Fang J. Five hub genes contributing to the oncogenesis and trastuzumab-resistance in gastric cancer. Gene. 2023;851:146942.PubMedCrossRef

32.

Wu X, Jian A, Tang H, Liu W, Liu F, Liu S, Wu H. A Multi-omics Study on the Effect of Helicobacter Pylori-related genes in the Tumor immunity on stomach adenocarcinoma. Front Cell Infect Microbiol. 2022;12:880636.PubMedPubMedCentralCrossRef

33.

Ding W, Jiang H, Ye N, Zhuang L, Yuan Z, Tan Y, Xue W, Xu X. Identification and analysis of crucial genes in H. Pylori-Associated Gastric Cancer using an Integrated Bioinformatics Approach. J Oncol. 2023;2023:8538240.PubMedPubMedCentralCrossRef

34.

Lau M, Le A, El-Serag HB. Noncardia gastric adenocarcinoma remains an important and deadly cancer in the United States: secular trends in incidence and survival. Am J Gastroenterol. 2006;101(11):2485–92.PubMedCrossRef

35.

Forman D. Helicobacter pylori: the gastric cancer problem. Gut. 1998;43(Suppl 1):S33–4.PubMedPubMedCentralCrossRef

36.

Ford AC, Yuan Y, Forman D, Hunt R, Moayyedi P. Helicobacter pylori eradication for the prevention of gastric neoplasia. Cochrane Database Syst Rev. 2020;7(7):CD005583.PubMed

37.

Lello E, Furnes B, Edna TH. Short and long-term survival from gastric cancer. A population-based study from a county hospital during 25 years. Acta Oncol. 2007;46(3):308–15.PubMedCrossRef

38.

Uozaki H, Barua RR, Minhua S, Ushiku T, Hino R, Shinozaki A, et al. Transcriptional factor typing with SOX2, HNF4aP1, and CDX2 closely relates to Tumor Invasion and Epstein-Barr Virus Status in Gastric Cancer. Int J Clin Exp Pathol. 2011;4:230–40.PubMedPubMedCentral

39.

Gomes AR, Zhao F, Lam EW. Role and Regulation of the Forkhead Transcription Factors FOXO3a and FOXM1 in Carcinogenesis and Drug Resistance. Chin J Cancer (2013) 32:365–70.10.5732/cjc.012.10277.

40.

Ji K, Zhang L, Zhang M, Chu Q, Li X, Wang W. Prognostic Value and Clinicopathological significance of p-stat3 among gastric carcinoma patients: a systematic review and Meta-analysis. Med (Baltim). 2016;95(5):e2641.CrossRef

41.

Song W, Ren J, Xiang R, Kong C, Fu T. Identification of pyroptosis-related subtypes, the development of a prognosis signature, and characterization of tumor microenvironment infiltration in colorectal cancer. Oncoimmunology. 2021;10(1):1987636.PubMedPubMedCentralCrossRef

42.

Lim WA, June CH. The principles of Engineering Immune cells to treat Cancer. Cell. 2017;168:724–40. https://doi.org/10.1016/j.cell.2017.01.016.CrossRefPubMedPubMedCentral

43.

Karimi-Zarchi M, Abbasi H, Javaheri A, et al. Association of IL-12B rs3212227 and IL-6 rs1800795 polymorphisms with susceptibility to Cervical Cancer: a systematic review and Meta-analysis. Asian Pac J Cancer Prev. 2020;21(5):1197–206.PubMedPubMedCentralCrossRef

44.

Runa F, Hamalian S, Meade K, Shisgal P, Gray PC, Kelber JA. Tumor microenvironment heterogeneity: challenges and opportunities. Curr Mol Biology Rep. 2017;3(4):218–29. https://doi.org/10.1007/s40610-017-0073-7.CrossRef

45.

Arneth B. Tumor Microenvironment. Medicina (Kaunas) (2019) 56(1):1–21.10.3390/medicina56010015.

46.

Jiang W, Liu K, Guo Q, et al. Tumor-infiltrating immune cells and prognosis in gastric cancer: a systematic review and meta-analysis. Oncotarget. 2017;8(37):62312–29.PubMedPubMedCentralCrossRef

47.

Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14:1014–22.PubMedPubMedCentralCrossRef

48.

Costa R, Carneiro BA, Agulnik M, Rademaker AW, Pai SG, Villaflor VM, Cristofanilli M, Sosman JA, Giles FJ. Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials. Oncotarget. 2017;8(5):8910–20.PubMedCrossRef

49.

Weber JS, O’Day S, Urba W, Powderly J, Nichol G, Yellin M, Snively J, Hersh E. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol. 2008;26(36):5950–6.PubMedCrossRef

50.

Wang M, Li Z, Peng Y, Fang J, Fang T, Wu J, Zhou J. Identification of immune cells and mRNA associated with prognosis of gastric cancer. BMC Cancer. 2020;20(1):206.PubMedPubMedCentralCrossRef

51.

Li X, Sun Z, Peng G, Xiao Y, Guo J, Wu B, Li X, Zhou W, Li J, Li Z, Bai C, Zhao L, Han Q, Zhao RC, Wang X. Single-cell RNA sequencing reveals a pro-invasive cancer-associated fibroblast subgroup associated with poor clinical outcomes in patients with gastric cancer. Theranostics. 2022;12(2):620–38.PubMedPubMedCentralCrossRef

52.

Chen C, Qin F, Singh S, Tang Y, Li H. CTNNBIP1-CLSTN1 functions as a housekeeping chimeric RNA and regulates cell proliferation through SERPINE2. Cell Death Discov. 2023;9(1):369.PubMedPubMedCentralCrossRef

Title: Comprehensive analysis of T-cell regulatory factors and tumor immune microenvironment in stomach adenocarcinoma
Authors: Shuchang Wang
Weifeng Zhang
Xinrui Wu
Zhu Zhu
Yuanbiao Chen
Wangrui Liu
Junnfei Xu
Li Chen
Chun Zhuang
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Gastric Cancer
Gastric Cancer
Published in: BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-024-12302-w

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2024

Prognostic value of plasma microRNAs for non-small cell lung cancer based on data mining models

Healthy lifestyles, systemic inflammation and breast cancer risk: a mediation analysis

Proficiency testing of diagnosis in histopathology and immunohistochemistry of breast pathology in China: results from a pilot work of National Single Disease Quality Control Program for breast cancer

Clinical characteristics and MRI based radiomics nomograms can predict iPFS and short-term efficacy of third-generation EGFR-TKI in EGFR-mutated lung adenocarcinoma with brain metastases

Can neoadjuvant chemoradiotherapy before lateral pelvic lymph node dissection improve local control and prognosis in rectal cancer patients with clinically suspected lateral lymph node metastasis? A multicenter lateral node study in China

Focused ultrasound versus the loop electrosurgical excision procedure to treat women with cervical high-grade squamous intraepithelial lesions under 40: a retrospective study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer